ElectroCore
Helping patients across the globe who suffer from pain and chronic conditions by harnessing the power of nVNS, innovation, and technology to develop safe and clinically backed treatments.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 429.0x EV/Revenue -7.8x EV/EBITDA | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $9.3m | Private Placement VC |
| Total Funding | 000k | ||
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 46 % | 56 % | 58 % | 87 % | 57 % | 22 % | 42 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (681 %) | (404 %) | (266 %) | (114 %) | (43 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (673 %) | (316 %) | (258 %) | (117 %) | (47 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 120 % | 47 % | 64 % | 33 % | 9 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
ElectroCore, Inc. (NASDAQ: ECOR) is a commercial-stage bioelectronic medicine company that was founded in 2005 by JP Errico, Thomas J. Errico, MD, Charles Theofilos, MD, and Peter Staats, MD. The founders, with backgrounds in medicine and spinal surgery, established the company based on the belief that neuromodulation could offer safer and more effective treatments for a variety of conditions. A key milestone for the company was its initial public offering (IPO) in 2018, which raised approximately $78 million.
The company's core business revolves around the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapy. This technology is designed to treat multiple conditions, primarily in the fields of neurology and metabolic disorders. ElectroCore's revenue is primarily generated from the sale of its products. Its main client base includes healthcare providers, with a significant portion of its sales directed towards government channels like the Department of Veterans Affairs (VA) and the Department of Defense (DoD). The company also pursues a direct-to-consumer model for its wellness products and employs a cash-pay model for patients whose insurance doesn't cover the therapy.
The flagship product is gammaCore™, a handheld device that allows patients to self-administer mild electrical stimulation to the vagus nerve in the neck. This action is intended to block pain signals and has received multiple FDA clearances for treating headache conditions. The first FDA clearance was granted in April 2017 for the acute treatment of pain associated with episodic cluster headaches in adults. Subsequent clearances expanded its use to include the prevention of cluster headaches, the treatment of migraines in adults and adolescents, and other headache disorders. Beyond prescription devices, ElectroCore markets Truvaga™, a general wellness nVNS product available directly to consumers for promoting calmness and better sleep. The company has also developed Quell®, an FDA-authorized device for reducing fibromyalgia symptoms, and TAC-STIM, a device designed for military use to enhance performance.
Keywords: non-invasive vagus nerve stimulation, bioelectronic medicine, neuromodulation, gammaCore, migraine treatment, cluster headache, medical device, neurology, pain management, Truvaga
Tech stack
Investments by ElectroCore
Edit